JCIM:中草药有效成分作用方式获重大研究进展
2013-03-16 MedSci MedSci原创
2013年3月15日 讯 /生物谷BIOON/ --近日,一项刊登在国际杂志Journal of Chemical Information and Modeling上的研究报告中,来自剑桥大学、马拉工业大学等处的研究者报道了其最新的研究突破,其克服了重重困难深入研究传统中草药(TCM)以及印度的草药,目的在于开发新型的更为有效的药物,相关研究成果刊登在了国际杂志Journal of Chemica
2013年3月15日 讯 /生物谷BIOON/ --近日,一项刊登在国际杂志Journal of Chemical Information and Modeling上的研究报告中,来自剑桥大学、马拉工业大学等处的研究者报道了其最新的研究突破,其克服了重重困难深入研究传统中草药(TCM)以及印度的草药,目的在于开发新型的更为有效的药物,相关研究成果刊登在了国际杂志Journal of Chemical Information and Modeling上。
研究者Andreas Bender和其同事解释道,传统中草药(TCM)为现代医学做出了巨大贡献,在国际上许多临床试验中都会用到中草药,比如说,科学家使用中草药中的一种提取物-青蒿琥酯,来替换奎宁作为一种治疗成年人和儿童的严重疟疾。传统的中药对人体健康非常有益,而且已有几千年的历史了。然而科学家并不清楚这些中草药在机体中如何作用以及其作用方式(MOA),这就大大限制了中草药在当今社会的使用。一种药物的作用方式对于理解其有益的作用以及副作用非常重要。
在这篇研究论文中,研究者描述了一种算法,其可以帮助我们理解和解释中草药的有效成分如何在机体中“工作”,而且也可以帮助理解传统抗炎中药的作用方式。这种算法可以慢慢给出分析数据,这样科学家就可以来预测中草药中的活性成分是如何影响机体的生化过程的。
报告中指出,如果确定了中草药中这些活性成分的作用方式,那么西方用药和中草药使用之间的鸿沟就会大大缩短了。相关研究由联合利华、马拉工业大学、马来西亚高等教育部门等机构提供资助。(生物谷Bioon.com)
Chemogenomics Approaches to Rationalizing the Mode-of-Action of Traditional Chinese and Ayurvedic Medicines
Fazlin Mohd Fauzi †, Alexios Koutsoukas , Robert Lowe ‡, Kalpana Joshi §, Tai-Ping Fan , Robert C. Glen , and Andreas Bender *
Traditional Chinese medicine (TCM) and Ayurveda have been used in humans for thousands of years. While the link to a particular indication has been established in man, the mode-of-action (MOA) of the formulations often remains unknown. In this study, we aim to understand the MOA of formulations used in traditional medicine using an in silico target prediction algorithm, which aims to predict protein targets (and hence MOAs), given the chemical structure of a compound. Following this approach we were able to establish several links between suggested MOAs and experimental evidence. In particular, compounds from the ’tonifying and replenishing medicinal’ class from TCM exhibit a hypoglycemic effect which can be related to activity of the ingredients against the Sodium-Glucose Transporters (SGLT) 1 and 2 as well as Protein Tyrosine Phosphatase (PTP). Similar results were obtained for Ayurvedic anticancer drugs. Here, both primary anticancer targets (those directly involved in cancer pathogenesis) such as steroid-5-alpha-reductase 1 and 2 were predicted as well as targets which act synergistically with the primary target, such as the efflux pump P-glycoprotein (P-gp). In addition, we were able to elucidate some targets which may point us to novel MOAs as well as explain side effects. Most notably, GPBAR1, which was predicted as a target for both ’tonifying and replenishing medicinal’ and anticancer classes, suggests an influence of the compounds on metabolism. Understanding the MOA of these compounds is beneficial as it provides a resource for NMEs with possibly higher efficacy in the clinic than those identified by single-target biochemical assays.
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
#重大研究#
116
#草药#
67
#JCI#
104
#研究进展#
120